1. LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.
- Author
-
Moerdler, Scott, Ewart, Michelle, Friedman, Debra L., Kelly, Kara, Pei, Qinglin, Peng, Mou, Zang, XingXing, and Cole, Peter D.
- Subjects
- *
HODGKIN'S disease , *LYMPHOCYTES , *INHIBITION of cellular proliferation , *CELL physiology , *T cells , *CHILDHOOD cancer , *CANCER prognosis , *PROTEIN expression , *PROGRAMMED death-ligand 1 - Abstract
LAG-3, through interaction with a variety of ligands, regulates T cell function via inhibition of T cell proliferation and activation. It has been demonstrated to be overexpressed on tumor infiltrating lymphocytes (TILs) of a variety of cancers with associated poor outcomes. The purpose of this study is to characterize the expression pattern and clinical significance of LAG-3 in pediatric Hodgkin lymphoma (HL). Patient tumor samples from Children's Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed for the expression of LAG-3 and PD-L1 using immunohistochemistry. 73/115 patients (63%) demonstrated positive LAG-3 staining. No demographic or survival outcome data were significantly associated with LAG-3 expression. Interestingly, patients with the lowest density of expression were found to have the worst EFS, and those with highest density of expression demonstrated the best EFS. There was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression. This project is innovative in its characterization of LAG-3 as an immune checkpoint target in pediatric HL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF